Additional file 1 of ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization

Additional file 1: Figure S1. Related to Fig. 1.Figure S2. Related to Fig. 2. Figure S3. Related to Fig. 4. Figure S4. Related to Fig. 6. Figure S5. Related to Fig. 7. Figure S6. Interference with the expression of ACVRL1 affects the survival and apoptosis ratio of CRC cells. Figure S7. Interference with the expression of ACVRL1 and GPX2 had no significant effect on the proliferation and differentiation of CRC cells under the treatment of Regorafenib.